Sugi Predict

Sugi Predict / Compounds / SCHEMBL24420107

SCHEMBL24420107

SCHEMBL24420107

Nc1cc(F)cnc1CO

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ AGBL2 Q5U5Z8 1/20 0.41
▸ DPP4 P27487 1/20 0.33
▸ NTRK1 P04629 2/20 0.31
▸ JAK2 O60674 1/20 0.31
▸ ADORA2A P29274 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29527098 1.00 AGBL2 (0.41) AGBL2DPP4NTRK1JAK2ADORA2A
SCHEMBL17887363 0.79 AGBL2 (0.41) AGBL2
SCHEMBL31539703 0.79 AGBL2 (0.38) AGBL2ADORA2A
SCHEMBL29941432 0.78 AGBL2 (0.43) AGBL2DPP4ADORA2A
SCHEMBL134813 0.78 AGBL2 (0.43) AGBL2DPP4ADORA2A
SCHEMBL15544538 0.75 AGBL2 (0.62) AGBL2DPP4
SCHEMBL22980910 0.75 AGBL2 (0.41) AGBL2
SCHEMBL27176898 0.75 HTT (0.43) DPP4JAK2
SCHEMBL23874363 0.75 SLC22A12 (0.41) AGBL2
SCHEMBL845650 0.71 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098018-A1 BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF CYTOKINETICS INC (US) 2026-04-09 — — US disclosed
US-12441691-B2 Bicyclic 1,4-diazepanones and therapeutic uses thereof CYTOKINETICS, INC. (US) 2025-10-14 — — US disclosed
US-20240368091-A1 BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF CYTOKINETICS, INC. 2024-11-07 — — US disclosed
US-11981644-B2 Bicyclic 1,4-diazepanones and therapeutic uses thereof CYTOKINETICS, INC. (US) 2024-05-14 — — US disclosed
EP-4240724-A1 BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF Cytokinetics, Inc. (US) 2023-09-13 — — EP disclosed
CN-116635378-A Bicyclic 1, 4-diazacycloheptanones and therapeutic uses thereof 赛特凯恩蒂克公司 2023-08-22 — — CN disclosed
US-20230083960-A1 BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF CYTOKINETICS, INC. 2023-03-16 — — US disclosed
WO-2022099011-A1 BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF CYTOKINETICS, INC. (US) 2022-05-12 — — WO disclosed
WO-2022099011-A1 BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF CYTOKINETICS, INC. (US) 2022-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368091-A1 BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF MYLK2, MUSK, MYLK AGBL2 4787/4885DPP4 2008/4885NTRK1 3670/4885
US-12441691-B2 Bicyclic 1,4-diazepanones and therapeutic uses thereof MYLK2, MUSK, MYLK AGBL2 4787/4885DPP4 2008/4885NTRK1 3670/4885
US-11981644-B2 Bicyclic 1,4-diazepanones and therapeutic uses thereof MYLK2, MUSK, MYLK AGBL2 4787/4885DPP4 2058/4885NTRK1 3738/4885
US-20260098018-A1 BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF MYLK2, TNNT2, RYR1 AGBL2 4626/4885DPP4 997/4885NTRK1 4013/4885
US-20230083960-A1 BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF MYLK2, MUSK, MYLK AGBL2 4787/4885DPP4 2008/4885NTRK1 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.